Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.

Tytuł :
Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
Autorzy :
Tosoian JJ; Department of Urology, University of Michigan, Ann Arbor, Michigan.; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Trock BJ; Johns Hopkins Brady Urological Institute, Baltimore, Maryland.
Morgan TM; Department of Urology, University of Michigan, Ann Arbor, Michigan.; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
Salami SS; Department of Urology, University of Michigan, Ann Arbor, Michigan.; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Tomlins SA; Department of Urology, University of Michigan, Ann Arbor, Michigan.; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Spratt DE; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.; Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Siddiqui J; Department of Urology, University of Michigan, Ann Arbor, Michigan.; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Kunju LP; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.; Department of Pathology, University of Michigan, Ann Arbor, Michigan.
Botbyl R; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Chopra Z; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Pandian B; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Eyrich NW; Department of Urology, University of Michigan, Ann Arbor, Michigan.
Longton G; Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Zheng Y; Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Palapattu GS; Department of Urology, University of Michigan, Ann Arbor, Michigan.; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
Wei JT; Department of Urology, University of Michigan, Ann Arbor, Michigan.; Dow Division of Health Services Research, University of Michigan, Ann Arbor, Michigan.
Niknafs YS; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Chinnaiyan AM; Department of Urology, University of Michigan, Ann Arbor, Michigan.; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.; Department of Pathology, University of Michigan, Ann Arbor, Michigan.; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Mar; Vol. 205 (3), pp. 732-739. Date of Electronic Publication: 2020 Oct 20.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Validation Study
Język :
English
Imprint Name(s) :
Publication: 2019- : [Philadelphia, PA] : Wolters Kluwer
Original Publication: Baltimore : Lippincott Williams & Wilkins
MeSH Terms :
Antigens, Neoplasm/*urine
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/*blood
Prostatic Neoplasms/*urine
Serine Endopeptidases/*urine
Aged ; Biomarkers, Tumor/blood ; Biomarkers, Tumor/urine ; Biopsy ; Digital Rectal Examination ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Predictive Value of Tests ; Prospective Studies ; Prostatic Neoplasms/pathology ; Referral and Consultation/statistics & numerical data ; Risk Assessment/methods ; Sensitivity and Specificity
References :
JCO Precis Oncol. 2019 Jun 12;3:. (PMID: 32914029)
Lancet. 2014 Dec 6;384(9959):2027-35. (PMID: 25108889)
Eur Urol. 2015 Dec;68(6):1083-8. (PMID: 25819722)
JAMA Oncol. 2018 Nov 1;4(11):1553-1568. (PMID: 29860482)
J Urol. 2015 Jan;193(1):87-94. (PMID: 25079939)
Eur Urol. 2015 Sep;68(3):464-70. (PMID: 25454615)
Clin Cancer Res. 2008 Oct 1;14(19):5977-83. (PMID: 18829476)
Eur Urol. 2016 Jul;70(1):45-53. (PMID: 25985884)
Clin Biochem Rev. 2008 Aug;29 Suppl 1:S83-7. (PMID: 18852864)
Urology. 2020 Nov;145:204-210. (PMID: 32777370)
Eur Urol Focus. 2020 Mar 15;6(2):267-272. (PMID: 30327280)
J Urol. 2015 Jul;194(1):65-72. (PMID: 25636659)
J Urol. 2016 Jun;195(6):1767-72. (PMID: 26724397)
JAMA Oncol. 2016 Jul 1;2(7):882-9. (PMID: 27032035)
Clin Cancer Res. 2016 Jan 1;22(1):243-9. (PMID: 26289069)
J Clin Oncol. 2005 Dec 20;23(36):9067-72. (PMID: 16172462)
J Urol. 2019 Aug;202(2):256-263. (PMID: 31026217)
Urol Clin North Am. 2016 Feb;43(1):17-38. (PMID: 26614026)
JAMA Oncol. 2017 Aug 1;3(8):1085-1093. (PMID: 28520829)
Eur Urol. 2019 Mar;75(3):358-367. (PMID: 30580902)
J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52. (PMID: 19815849)
Eur Urol. 2019 May;75(5):712-720. (PMID: 30509763)
Eur Urol Focus. 2019 Jul;5(4):592-599. (PMID: 29226826)
Eur Urol. 2020 Jan;77(1):78-94. (PMID: 31326219)
Biom J. 2005 Aug;47(4):458-72. (PMID: 16161804)
N Engl J Med. 2018 May 10;378(19):1767-1777. (PMID: 29552975)
J Urol. 2018 Apr;199(4):947-953. (PMID: 29061540)
JAMA. 2018 May 8;319(18):1901-1913. (PMID: 29801017)
JAMA. 2018 May 8;319(18):1914-1931. (PMID: 29801018)
J Urol. 2015 Apr;193(4):1163-9. (PMID: 25463993)
Clin Chem. 2015 Dec;61(12):1446-52. (PMID: 26510957)
Clin Chem. 2011 Jan;57(1):1-3. (PMID: 21078839)
Eur Urol. 2017 May;71(5):697-700. (PMID: 27477529)
Grant Information :
T32 CA180984 United States CA NCI NIH HHS; R35 CA231996 United States CA NCI NIH HHS; R21 AI080984 United States AI NIAID NIH HHS; U01 CA214170 United States CA NCI NIH HHS; R01 CA236558 United States CA NCI NIH HHS; P50 CA186786 United States CA NCI NIH HHS
Contributed Indexing :
Keywords: biomarkers*; biopsy*; early detection of cancer*; prostate-specific antigen*; prostatic neoplasms*; tumor*
Substance Nomenclature :
0 (Antigens, Neoplasm)
0 (Biomarkers, Tumor)
0 (prostate cancer antigen 3, human)
EC 3.4.21.- (Serine Endopeptidases)
EC 3.4.21.- (TMPRSS2 protein, human)
EC 3.4.21.77 (Prostate-Specific Antigen)
Entry Date(s) :
Date Created: 20201020 Date Completed: 20210414 Latest Revision: 20210611
Update Code :
20210611
PubMed Central ID :
PMC8189629
DOI :
10.1097/JU.0000000000001430
PMID :
33080150
Czasopismo naukowe
Purpose: The MyProstateScore test was validated for improved detection of clinically significant (grade group ≥2) prostate cancer relative to prostate specific antigen based risk calculators. We sought to validate an optimal MyProstateScore threshold for clinical use in ruling out grade group ≥2 cancer in men referred for biopsy.
Materials and Methods: Biopsy naïve men provided post-digital rectal examination urine prior to biopsy. MyProstateScore was calculated using the validated, locked multivariable model including only serum prostate specific antigen, urinary prostate cancer antigen 3 and urinary TMPRSS2:ERG. The MyProstateScore threshold approximating 95% sensitivity for grade group ≥2 cancer was identified in a training cohort, and performance was measured in 2 external validation cohorts. We assessed the 1) overall biopsy referral population and 2) population meeting guideline based testing criteria (ie, prostate specific antigen 3-10, or <3 with suspicious digital rectal examination).
Results: Validation cohorts were prospectively enrolled from academic (977 patients, median prostate specific antigen 4.5, IQR 3.1-6.0) and community (548, median prostate specific antigen 4.9, IQR 3.7-6.8) settings. In the overall validation population (1,525 patients), 338 men (22%) had grade group ≥2 cancer on biopsy. The MyProstateScore threshold of 10 provided 97% sensitivity and 98% negative predictive value for grade group ≥2 cancer. MyProstateScore testing would have prevented 387 unnecessary biopsies (33%), while missing only 10 grade group ≥2 cancers (3.0%). In 1,242 patients meeting guideline based criteria, MyProstateScore ≤10 provided 96% sensitivity and 97% negative predictive value, and would have prevented 32% of unnecessary biopsies, missing 3.7% of grade group ≥2 cancers.
Conclusions: In a large, clinically pertinent biopsy referral population, MyProstateScore ≤10 provided exceptional sensitivity and negative predictive value for ruling out grade group ≥2 cancer. This straightforward secondary testing approach would reduce the use of more costly and invasive procedures after screening with prostate specific antigen.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies